Erenumab for migraine disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 22 registered trials.

Why this status

  1. 28 May 2015: Trial registered, NCT02456740
  2. 29 Jun 2015: Trial registered, NCT02483585
  3. 17 Jul 2015: Trial started, NCT02456740
  4. 20 Jul 2015: Trial started, NCT02483585
  5. 20 Mar 2017: Trial started, NCT03096834
  6. 30 Mar 2017: Trial registered, NCT03096834
  7. 6 Nov 2017: Trial registered, NCT03333109
  8. 8 Feb 2018: Trial started, NCT03333109
  9. 6 Feb 2019: Trial registered, NCT03832998
  10. 11 Feb 2019: Trial registered, NCT03836040
  11. 7 Mar 2019: Trial registered, NCT03867201
  12. 6 Jun 2019: Trial registered, NCT03977649
  13. 19 Jul 2019: Trial started, NCT03836040
  14. 30 Jul 2019: Trial started, NCT03977649
  15. 26 Aug 2019: Trial started, NCT03867201
  16. 5 Sep 2019: Trial started, NCT03832998
  17. 10 Sep 2019: Trial registered, NCT04084314
  18. 30 Sep 2019: Trial started, NCT04084314
  19. 5 Feb 2020: Trial registered, NCT04252742
  20. 12 Feb 2020: Trial registered, NCT04265755
  21. 15 Sep 2020: Trial started, NCT04252742
  22. 25 Sep 2020: Trial started, NCT04603976
  23. 22 Oct 2020: Trial started, NCT04674020
  24. 26 Oct 2020: Trial started, NCT04265755
  25. 27 Oct 2020: Trial registered, NCT04603976
  26. 17 Dec 2020: Trial registered, NCT04674020
  27. 1 Apr 2021: Trial registered, NCT04825678
  28. 11 Jun 2021: Trial started, NCT04825678

The trials

NCT01688739: Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients

State
Completed
Phase
Phase 1
People
61 taking part
Started
13 Mar 2012
Primary completion
27 Mar 2013
Arms
Erenumab
Results
Posted on the registry
  1. 13 Mar 2012: Trial started
  2. 20 Sep 2012: Trial registered
  3. 27 Mar 2013: Trial completed
  4. 18 Jan 2019: Trial results posted

NCT01723514: Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients

State
Completed
Phase
Phase 1
People
48 taking part
Started
14 Nov 2012
Primary completion
10 Jul 2014
Arms
Erenumab
Results
Posted on the registry
  1. 8 Nov 2012: Trial registered
  2. 14 Nov 2012: Trial started
  3. 10 Jul 2014: Trial completed
  4. 18 Jan 2019: Trial results posted

NCT01952574: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

State
Completed
Phase
Phase 2
People
483 taking part
Started
6 Aug 2013
Primary completion
25 Sep 2014
Arms
CHU Substudy: Erenumab 140 mg PFS, CHU Substudy: Erenumab 140 mg AI/Pen
Results
Posted on the registry
  1. 6 Aug 2013: Trial started
  2. 30 Sep 2013: Trial registered
  3. 10 Jul 2018: Trial results posted
  4. 12 Nov 2019: Trial completed

NCT02456740: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

State
Completed
Phase
Phase 3
People
955 taking part
Started
17 Jul 2015
Primary completion
5 Sep 2016
Arms
Erenumab 70 mg QM, Erenumab 140 mg QM
Results
Posted on the registry
  1. 28 May 2015: Trial registered
  2. 17 Jul 2015: Trial started
  3. 19 Jun 2017: Trial completed
  4. 10 Jul 2018: Trial results posted

NCT02483585: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention

State
Completed
Phase
Phase 3
People
577 taking part
Started
20 Jul 2015
Primary completion
11 Jul 2016
Arms
Erenumab
Results
Posted on the registry
  1. 29 Jun 2015: Trial registered
  2. 20 Jul 2015: Trial started
  3. 20 Mar 2017: Trial completed
  4. 25 Jun 2018: Trial results posted

NCT02542605: To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients

State
Completed
Phase
Phase 1
People
35 taking part
Started
11 Nov 2015
Primary completion
28 Sep 2017
Arms
Erenumab
Results
Posted on the registry
  1. 7 Sep 2015: Trial registered
  2. 11 Nov 2015: Trial started
  3. 8 Nov 2017: Trial completed
  4. 3 Jun 2019: Trial results posted

NCT02630459: A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention

State
Completed
Phase
Phase 2
People
475 taking part
Started
6 Jan 2016
Primary completion
25 Sep 2017
Arms
DBTP: Erenumab 28 mg QM, DBTP: Erenumab 70 mg QM, DBTP: Erenumab 140 mg QM, Open-Label Treatment Phase (OLTP): Erenumab 70-140 mg QM, CHU Sub-Study: Two 70 mg/mL AI/pens, CHU Sub-Study: One 140 mg/mL AI/pen
Results
Posted on the registry
  1. 15 Dec 2015: Trial registered
  2. 6 Jan 2016: Trial started
  3. 13 Mar 2019: Trial results posted
  4. 5 Jun 2019: Trial completed

NCT03096834: A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies

State
Completed
Phase
Phase 3
People
246 taking part
Started
20 Mar 2017
Primary completion
18 Jan 2018
Arms
AMG334 140 mg DB, AMG334 140 mg DB cont on AMG334 140 mg, Placebo in DB to AMG334 140 mg
Results
Posted on the registry
  1. 20 Mar 2017: Trial started
  2. 30 Mar 2017: Trial registered
  3. 28 Jan 2021: Trial completed
  4. 18 Feb 2022: Trial results posted

NCT03333109: Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients

State
Completed
Phase
Phase 3
People
900 taking part
Started
8 Feb 2018
Primary completion
13 Jan 2020
Arms
AMG334 70 mg, AMG334 140 mg
Results
Posted on the registry
  1. 6 Nov 2017: Trial registered
  2. 8 Feb 2018: Trial started
  3. 13 Jan 2020: Trial completed
  4. 9 Mar 2021: Trial results posted

NCT03832998: Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

State
Completed
Phase
Phase 3
People
284 taking part
Started
5 Sep 2019
Primary completion
8 Jan 2025
Arms
Dose Level 1, Dose Level 2
Results
Posted on the registry
  1. 6 Feb 2019: Trial registered
  2. 5 Sep 2019: Trial started
  3. 7 Jan 2026: Trial completed
  4. 28 Oct 2026: Trial results posted

NCT03836040: Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

State
Under way
Phase
Phase 3
People
457 taking part
Started
19 Jul 2019
Primary completion
19 Nov 2025
Arms
Dose level 1, Dose level 2
Results
None posted
  1. 11 Feb 2019: Trial registered
  2. 19 Jul 2019: Trial started

NCT03867201: Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients

State
Completed
Phase
Phase 3
People
557 taking part
Started
26 Aug 2019
Primary completion
11 Aug 2021
Arms
Erenumab
Results
Posted on the registry
  1. 7 Mar 2019: Trial registered
  2. 26 Aug 2019: Trial started
  3. 30 Apr 2024: Trial completed
  4. 11 May 2025: Trial results posted

NCT03912337: Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine

State
Stopped early
Phase
Phase 4
People
29 taking part
Started
4 Dec 2019
Primary completion
28 Jul 2021
Arms
Erenumab
Results
Posted on the registry
  1. 11 Apr 2019: Trial registered
  2. 4 Dec 2019: Trial started
  3. 28 Jul 2021: Trial terminated
  4. 20 Jul 2022: Trial results posted

NCT03977649: A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients

State
Completed
Phase
Phase 4
People
62 taking part
Started
30 Jul 2019
Primary completion
5 Jul 2021
Arms
erenumab
Results
None posted
  1. 6 Jun 2019: Trial registered
  2. 30 Jul 2019: Trial started
  3. 5 Jul 2021: Trial completed

NCT04084314: Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study

State
Completed
Phase
Phase 4
People
701 taking part
Started
30 Sep 2019
Primary completion
23 Feb 2023
Arms
Erenumab
Results
Posted on the registry
  1. 10 Sep 2019: Trial registered
  2. 30 Sep 2019: Trial started
  3. 13 Mar 2023: Trial completed
  4. 6 Feb 2024: Trial results posted

NCT04114630: Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab

State
Withdrawn before it started
Phase
Phase 3
People
0 taking part
Started
30 Oct 2019
Primary completion
6 Dec 2021
Arms
erenumab
Results
None posted
  1. 3 Oct 2019: Trial registered
  2. 1 Jun 2020: Trial withdrawn

NCT04252742: Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

State
Completed
Phase
Phase 4
People
512 taking part
Started
15 Sep 2020
Primary completion
26 Oct 2023
Arms
Erenumab
Results
Posted on the registry
  1. 5 Feb 2020: Trial registered
  2. 15 Sep 2020: Trial started
  3. 26 Oct 2023: Trial completed
  4. 30 Aug 2024: Trial results posted

NCT04265755: Biomarker and Genetic Predictors of Erenumab Treatment Response

State
Completed
Phase
Phase 4
People
1,406 taking part
Started
26 Oct 2020
Primary completion
18 Jan 2023
Arms
Single arm
Results
Posted on the registry
  1. 12 Feb 2020: Trial registered
  2. 26 Oct 2020: Trial started
  3. 18 Jan 2023: Trial completed
  4. 7 Jun 2024: Trial results posted

NCT04603976: Registry for Migraine - Clinical Core

State
State not given
Phase
Phase 4
People
1,000 planned
Started
25 Sep 2020
Primary completion
Oct 2022
Arms
Single-Arm
Results
None posted
  1. 25 Sep 2020: Trial started
  2. 27 Oct 2020: Trial registered

NCT04674020: Registry for Migraine - Structural and Functional MRI Before and After Erenumab Treatment

State
State not given
Phase
Phase 4
People
250 planned
Started
22 Oct 2020
Primary completion
22 Jul 2025
Arms
Single-Arm
Results
None posted
  1. 22 Oct 2020: Trial started
  2. 17 Dec 2020: Trial registered

NCT04825678: A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine

State
Completed
Phase
Phase 4
People
240 taking part
Started
11 Jun 2021
Primary completion
28 Sep 2023
Arms
Erenumab
Results
Posted on the registry
  1. 1 Apr 2021: Trial registered
  2. 11 Jun 2021: Trial started
  3. 28 Sep 2023: Trial completed
  4. 19 Sep 2024: Trial results posted

NCT04920331: Study of Intravenous Erenumab in Patients With Status Migrainosus

State
Withdrawn before it started
Phase
Phase 1
People
0 taking part
Started
7 Sep 2021
Primary completion
4 Feb 2022
Arms
Erenumab
Results
None posted
  1. 9 Jun 2021: Trial registered
  2. 7 Sep 2021: Trial started
  3. 22 Feb 2022: Trial withdrawn

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as AMG334 (70 mg) Pre-Filled Syringe (PFS), Erenumab AI/Pen, Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Erenumab PFS, erenumab 70mg/mL.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.